

Product datasheet for TP727877

Lilrb4a Mouse Recombinant Protein

Product data:

Product Type: Recombinant Proteins

Description: Recombinant Mouse LILRB4 (C-Fc)

Species: Mouse

Expression cDNA Clone

or AA Sequence:

Gly24-Lys238

Tag: C-Fc

Buffer: Lyophilized from a 0.2 um filtered solution of 50 mM Tris-HCl,100mM Glycine,pH7.5.

Note: Recombinant Mouse Leukocyte Immunoglobulin-like Receptor Subfamily B Member 4 is

produced by our Mammalian expression system and the target gene encoding Gly24-Lys238

is expressed with a Fc tag at the C-terminus.

Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 Storage:

weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of

reconstituted samples are stable at < -20°C for 3 months.

12 months from date of despatch Stability:

Locus ID: 14728 **UniProt ID:** Q64281

Synonyms: Leukocyte immunoglobulin-like receptor subfamily B member 4; Mast cell surface

glycoprotein Gp49B; CD85k; Lilrb4; Gp49b



OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn

Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com





Summary:

Mouse Leukocyte Immunoglobulin-like Receptor Subfamily B Member 4 (LILRB4/CD85k/ILT3) is an approximately transmembrane glycoprotein that negatively regulates immune cell activation. Mouse LILRB4 consists of a 215 amino acid (aa) extracellular domain with two Iglike domains, a 22 aa transmembrane segment, and a 75 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM). Within the ECD, mouse LILRB4 shares 45% and 77% aa sequence identity with human and rat LILRB4, respectively. Alternative splicing of mouse LILRB4 generates a potentially soluble isoform that lacks the transmembrane segment. LILRB4 is expressed on dendritic cells (DC), monocytes, macrophages, and vascular endothelial cells (EC). Ligation of LILRB4 triggers ITIM-mediated inhibition of cellactivating signaling, leading to enhanced immune tolerance and reduced allogeneic graft rejection. Soluble LILRB4 induces the differentiation of CD8+ T suppressor cells (Ts) that can inhibit the effector functions of CD4+ Th cells and CD8+ CTL. In turn, CD8+ Ts cells induce LILRB4 up-regulation and a tolerogenic phenotype in monocytes, DC, and EC.